Sign in
CompletedNo phase

Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia

Key facts

Who runs it
Unity Health Toronto
Where
Augusta, Aurora, Baltimore, Chapel Hill, NC, Cincinnati, Little Rock, Los Angeles, Monkton, New Haven, Phoenix, Rochester, Salt Lake City, San Francisco, and St Louis, United StatesSee the 14 sitesAlso in 2 other countries, 5 sites
Trial code
Status
Completed
People taking part
2,272 people enrolled
Started
8 Apr 2010
Ended
30 Jun 2025
Type of study
Observational, 2 groups
Record updated
22 April 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Definite clinical HHT diagnosis (at least 3 Curacao criteria)or genetic diagnosis of HHT or
  • Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT and Presence of Brain Arteriovenous Malformation
  • Able to provide informed consent; Curacao criteria:
  • spontaneous recurrent nosebleeds
  • mucocutaneous telangiectasia at characteristic sites (lips, oral cavity or the nose)
  • visceral involvement such as pulmonary, hepatic or CNS BAVM; and (d) an affected first degree relative by same criteria; Willingness
  • Willingness to participate in the study and ability to give informed consent

Who cannot take part

  • Patients not complying with Inclusion criteria

Where in United States

Also in 2 other countries, 5 sites

  • Georgia Regents UniversityAugusta, United States
  • UCHealth Pulmonary Vascular Disease Clinic - Anschutz MedicalAurora, United States
  • Johns Hopkins University School Of MedicineBaltimore, United States
  • University of North Carolina at Chapel HillChapel Hill, NC, United States
  • Cincinnati Children's Hospital Medical CenterCincinnati, United States
  • University of Arkansas for Medical SciencesLittle Rock, United States
  • David Geffen School of Medicine at University of California, Los AngelesLos Angeles, United States
  • HHT Foundation International, Inc.Monkton, United States
  • Yale UniversityNew Haven, United States
  • Barrow Neurological InstitutePhoenix, United States
  • Mayo ClinicRochester, United States
  • University of UtahSalt Lake City, United States
  • University of California San FranciscoSan Francisco, United States
  • Washington University School of MedicineSt Louis, United States

About the trial

What the trial wants to find out

This study is one of the three projects of an NIH Rare Disease Clinical Research Consortium. A "consortium" is a group of centres sharing information and resources to perform research. The consortium research focuses on brain blood vessel malformations in three different rare diseases.

Read full original descriptionShow less

The focus of this specific study is on Hemorrhagic Telangiectasia (HHT).

HHT is a condition characterized by blood vessel malformations, called telangiectasia and arteriovenous malformations (AVMs), occurring in the brain, nose, lungs, stomach, bowels and liver. Brain AVMs (BAVMs) in HHT are difficult to study because they are rare, affecting approximately 10% of people with HHT. While other types of BAVMs have been studied in depth, studies in the HHT population have been very small. Here, we propose the first large-scale collaboration by joining with 12 HHT Centers of Excellence in North America to perform a large study of risk factors for bleeding from BAVMs, called intracranial hemorrhage (ICH) in HHT patients.

The current standard of clinical practice across North America, is to screen all HHT patients for BAVMs with magnetic resonance imaging (MRI). If BAVMs are detected, patients are referred to a multidisciplinary neurovascular team for consideration for treatment. Treatment decisions are made on a case by case basis, balancing risks of complications from the BAVM with risks of therapy, but are limited by the few studies available in HHT. We hope that the knowledge we obtain about the risk factors for intracranial bleeding in these patients from this larger study will help us to improve the care of HHT patients.

We plan to study risk factors for rupture of BAVMs, including primarily genetics and imaging characteristics of the BAVMs. Knowledge about risk factors will help in the care and management of HHT patients. This will be achieved through the collection of health information to construct a HHT database, blood sampling and banking (through the National Institute of Neurological Disorders and Stroke [NINDS]), and through genetic analysis at the University of California San Francisco.

The 2 groups in the trial

  • HHT- Brain Arteriovenous Malformation

    1. Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT and 2. Presence of Brain Arteriovenous Malformation

  • HHT -NO BAVM

    1\. Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia (RDCRN# 6203, Protocol Version Date 07Jan10)
Record updated
22 April 2026